Study: NCT06262685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines
Description: Atorvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines
Description: Simvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines
Description: Pitavastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines
Description: Rosuvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines
Description: Pravastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines
Description: Lovastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines
Description: Fluvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of atorvastatin
Description: Subject allocated to this arm will receive the atorvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of simvastatin
Description: Subject allocated to this arm will receive the simvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of pitavastatin
Description: Subject allocated to this arm will receive the pitavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of rosuvastatin
Description: Subject allocated to this arm will receive the rosuvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of prasavastatin
Description: Subject allocated to this arm will receive the prasavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of lovastatin
Description: Subject allocated to this arm will receive the lovastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of fluvastatin
Description: Subject allocated to this arm will receive the fluvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.